Trial Profile

Clinical Trials Insight: 700056268

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 18 May 2010

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Escitalopram (Primary) ; Paroxetine
Indications Major depressive disorder
Focus Registrational; Therapeutic Use
Sponsors Mochida Pharmaceutical

Most Recent Events

18 May 2010 New trial record
17 May 2010 According to a Lundbeck A/S media release, based on the positive results of this trial, Mochida Pharmaceuticals plans to file regulatory approval for escitalopram by the first quarter 2011.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com